Flow of patients through the study (CONSORT diagram). ∗Denotes that nonconforming product is defined as any product wherein one of the CD8 or CD4 cell components did not meet one of the requirements to be considered liso-cel but was considered appropriate for infusion. †Denotes that 7 patients among those who received nonconforming product in TRANSCEND continued in the long-term follow-up study. ‡Denotes that 1 patient who died after study completion was included among deaths occurring in the posttreatment-emergent period.